Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, 12-Week Study to Evaluate the Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Chinese Participants With Chronic Migraine

NCT04829747 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT04829747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04829747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, 12-Week Study to Evaluate the Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Chinese Participants With Chronic Migraine
Lead sponsor
Allergan
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2021
Completion date
January 20, 2022
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine